NASDAQ · NVO
Healthcare · Drug Manufacturers - General
$39.40
Down-$1.23 (-3.12%)
Updated Sep 23, 2026, 11:30 PM
SID Score
6.3/10
Composite research score
Smart Money
60/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NVO closed at $39.40 after 20 trading sessions, down 19.03% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 22, 2026 | $39.50 | $39.89 | $39.105 | $39.40 | 24.46M |
| Sep 21, 2026 | $41.05 | $41.17 | $39.54 | $39.80 | 49.34M |
| Sep 18, 2026 | $43.50 | $43.54 | $42.78 | $43.24 | 10.37M |
| Sep 17, 2026 | $41.98 | $43.44 | $41.96 | $43.19 | 12.95M |
| Sep 16, 2026 | $42.47 | $42.72 | $41.47 | $41.71 | 11.67M |
| Sep 15, 2026 | $42.725 | $43.00 | $42.40 | $42.53 | 8.86M |
| Sep 14, 2026 | $43.66 | $43.71 | $43.0701 | $43.45 | 6.56M |
| Sep 11, 2026 | $43.195 | $43.4951 | $42.7216 | $43.07 | 11.03M |
| Sep 10, 2026 | $44.60 | $44.82 | $44.01 | $44.01 | 6.58M |
| Sep 9, 2026 | $45.00 | $45.395 | $44.52 | $44.56 | 8.83M |
| Sep 8, 2026 | $45.58 | $45.91 | $45.145 | $45.16 | 10.35M |
| Sep 4, 2026 | $46.35 | $46.74 | $46.0417 | $46.60 | 6.22M |
| Sep 3, 2026 | $47.99 | $48.00 | $46.565 | $47.51 | 8.77M |
| Sep 2, 2026 | $46.05 | $47.005 | $45.91 | $46.77 | 13.6M |
| Sep 1, 2026 | $45.80 | $46.16 | $45.065 | $45.12 | 9.36M |
| Aug 31, 2026 | $45.28 | $45.61 | $44.95 | $45.33 | 7.61M |
| Aug 28, 2026 | $46.17 | $46.21 | $45.405 | $45.61 | 8.5M |
| Aug 27, 2026 | $45.97 | $46.33 | $45.70 | $46.26 | 13.02M |
| Aug 26, 2026 | $47.80 | $48.04 | $46.87 | $47.19 | 8.88M |
| Aug 25, 2026 | $47.84 | $48.66 | $47.56 | $48.66 | 15.53M |
The latest Smart Investors Daily articles mentioning NVO.
NVO research
Company profile and research snapshot.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 13, 2026 | BERENBERG | Buy | — |
| Jul 13, 2026 | JYSKE BANK | Hold | — |
| Jul 12, 2026 | GUGGENHEIM SECURITIES LLC | Neutral | — |
| Jul 5, 2026 | EQUISIGHTS | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Novo Nordisk (NYSE:NVO) would be open to considering a direct listing of its shares on the New York Stock Exchange, Chief Executive Mike Doustdar told the Financial Times in an interview published Wednesday. Doustdar said he could see advantages to such a move when asked about the possibility, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its U.
SeekingAlpha · Sep 23, 2026
Novo Nordisk A/S outlook: CMD didnât convince as Street sees 2026 revenue dip. Click for this NVO stock update and see if it is the right stock for you.
Yahoo · Sep 23, 2026
Novo Nordisk (NVO) has won approval from Singapore authorities for the use of its weight-loss drug,
Benzinga · Sep 23, 2026
Anthropic and OpenEvidence are giving doctors in nearly 100 poorer nations free access to medical guidance tools.
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S shares have experienced sustained downward pressure across multiple timeframes, with the stock trading at $39.40 per SID market data. NVO has declined 15.7% over the past month and 16.91% over the trailing three-month period, while the one-year return stands at a steep negative 35.83%. The stock is now trading well below both its 50-day moving average of $46.51 and its 200-day moving average of $46.07, confirming a bearish technical posture. The 14-day relative strength index registers at 30.0, placing NVO at the conventional oversold threshold. Average daily trading volume of approximately 16.69 million shares indicates robust liquidity despite the sell-off. Notably, the stock carries a beta of just 0.352 per SID market data, meaning it has historically exhibited significantly lower volatility than the broader market, making the magnitude of this decline particularly noteworthy for a traditionally defensive healthcare name.
Following its prolonged sell-off, Novo Nordisk's valuation metrics have compressed meaningfully. The stock currently trades at a price-to-earnings ratio of approximately 12.76, per SID market data, a level notably below historical averages for large-cap pharmaceutical companies in the Healthcare sector. The PEG ratio stands at 2.05, suggesting that the earnings multiple remains elevated relative to expected growth rates, according to SID market data. NVO's price-to-book ratio of 8.43 reflects the asset-light, intellectual-property-intensive nature of its pharmaceutical business model. The company offers a dividend yield of approximately 3.66% based on SEC filings, which has risen mechanically as the share price has declined. With a market capitalization of roughly $223.5 billion, Novo Nordisk remains one of the largest healthcare companies globally. The compressed P/E ratio paired with the elevated PEG ratio indicates the market is currently pricing in slower forward earnings growth relative to the company's recent trajectory.
Novo Nordisk's composite smart money score registers at 60 out of 100 with a neutral signal, per SID market data, indicating mixed positioning among sophisticated market participants. The institutional component scores a strong 23.0 out of 25, reflecting continued robust ownership and engagement from large fund managers, according to 13F institutional filings. In contrast, the insider activity component scores a more moderate 12.5 out of 25, suggesting neither aggressive buying nor notable selling from company executives and directors based on SEC Form 4 filings. Dark pool activity scores 12.0 out of 25, indicating average levels of off-exchange institutional trading interest. Congressional trading activity also scores at a neutral 12 out of 25. The divergence between the high institutional score and the moderate readings across other smart money categories suggests that large asset managers maintain conviction in their NVO positions, while other informed participant groups have adopted a more measured stance during the stock's recent period of significant price weakness.
Novo Nordisk's forward earnings calendar shows four consecutive quarterly reporting dates clustered in August 2026, with the earliest report scheduled for August 18, 2026, according to company earnings reports. Analyst consensus estimates project earnings of $0.81 per share for each of the four upcoming quarters, per analyst estimates, reflecting expectations for stable sequential earnings performance. This uniform estimate across quarters totals an implied annual earnings figure of approximately $3.24 per share, which aligns with the current P/E ratio of 12.76 at the stock's $39.40 price. No actual results have been reported yet for these periods, leaving no earnings surprise data available. The flat quarterly estimate trajectory suggests analysts currently model consistent revenue and margin delivery rather than meaningful sequential acceleration or deceleration. Investors will closely monitor whether the company's GLP-1 receptor agonist franchise, the primary growth driver, can sustain the earnings trajectory embedded in current consensus forecasts.
Recent Wall Street analyst activity on Novo Nordisk reflects a predominantly constructive but not unanimous outlook. On July 13, 2026, Rothschild & Co Redburn maintained its Buy rating, while Berenberg also reiterated a Buy recommendation on the same date, per Wall Street analyst reports. However, Jyske Bank downgraded NVO to Hold from Buy on July 13, representing the sole negative ratings change in the recent period. Guggenheim Securities LLC maintained its Neutral rating on July 12, 2026, according to SID consensus data. Earlier, on July 5, Equisights reiterated its Buy rating. Of the five most recent analyst actions, three represent maintained Buy ratings, one is a maintained Neutral, and one constitutes a downgrade to Hold. This distribution suggests that the majority of covering analysts view the recent price decline as inconsistent with fundamental value, though the Jyske Bank downgrade and Guggenheim's Neutral stance indicate some institutional research desks see limited near-term catalysts for recovery.
The latest Smart Investors Daily articles mentioning NVO.
